Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Y Yuen

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Analytical Chemistry|August 2, 2016
Development and Application of Ultra-Performance Liquid Chromatography-TOF MS for Precision Large Scale Urinary Metabolic PhenotypingMatthew R Lewis, Jake T M Pearce, Konstantina Spagou, et al.
Npj Viruses|June 20, 2025
Longitudinal kinetics of the viral infection biomarker 3'-deoxy-3',4'-didehydro-cytidine in SARS-CoV-2, influenza A virus and RSV human challenge modelsRavi Mehta, Elena Chekmeneva, Stephanie Ascough, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|December 4, 2025
Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancerW Yeo, Y H Y Chan, R C Y Leung, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Analytical Chemistry|August 2, 2016
Development and Application of Ultra-Performance Liquid Chromatography-TOF MS for Precision Large Scale Urinary Metabolic PhenotypingMatthew R Lewis, Jake T M Pearce, Konstantina Spagou, et al.
Npj Viruses|June 20, 2025
Longitudinal kinetics of the viral infection biomarker 3'-deoxy-3',4'-didehydro-cytidine in SARS-CoV-2, influenza A virus and RSV human challenge modelsRavi Mehta, Elena Chekmeneva, Stephanie Ascough, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|December 4, 2025
Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancerW Yeo, Y H Y Chan, R C Y Leung, et al.
Pageof 7